Explorer les evidences

The first SARS-CoV-2 cases in Seychelles were reported on the 14th of March 2020.

KenyaCOVID-19observé 2020-03-14publié 2022Viruseseurope_pmcdocument de 3 observationsDOI 10.3390/v14061318

1 000 introductionsMore than 1000 SARS-CoV-2 introductions occurred in Kenya between March 2020 and September 2022.

KenyaCOVID-19observé March 2020 – September 2022publié 2022The genomic epidemiology of SARS-CoV-2 variants of concern in Kenyaeurope_pmcdocument de 8 observationsDOI 10.1101/2022.10.26.22281446

26,6 %26.6% of COVID-19 negative DKA patients had moderate DKA.

KenyaCOVID-19 · diabetic ketoacidosis (DKA)observé during COVID-19 pandemicpublié 2024BMC endocrine disordersPubMeddocument de 16 observations

4,7 %Few pregnant women living with HIV in Kenya reported delaying antenatal care because of COVID-19 (4.7%).

KenyaCOVID-19 · VIH/sidaobservé October 2020 to July 2022publié 2024BMC pregnancy and childbirthPubMeddocument de 4 observations

27 %Among 2340 contacts listed for 577 cases in Kenya, 632 contacts (27.0%) were traced.

KenyaCOVID-19publié 2022Journal of global healthPubMeddocument de 24 observations

20 %20% of the RT-PCR negative samples were paired with positive serum IgG antibody samples in the Coastal part of Kenya between 17th March 2020 and 30th June 2021.

KenyaCOVID-19observé 17th March 2020 to 30th June 2021publié 2022Wellcome open researcheurope_pmcdocument de 10 observations

1,6 aORPatients aged >64 years were more likely to have SARS-CoV-2 infection compared to those aged 12–24 years, with an adjusted odds ratio of 1.60.

KenyaCOVID-19observé July 2022 to October 2023publié 2026VaccinePubMeddocument de 8 observations

7 737 casesA total of 7737 individuals were SARS-CoV-2 positive by RT-PCR out of 99,694 naso-pharyngeal/oro-pharyngeal swabs tested in the Coastal part of Kenya between 17th March 2020 and 30th June 2021.

KenyaCOVID-19observé 17th March 2020 to 30th June 2021publié 2022Wellcome open researcheurope_pmcdocument de 10 observations

3,2 %The case fatality rate of COVID-19 in Kenya was 3.2% as of 30th June 2020.

KenyaCOVID-19observé 30th June 2020publié 2020The Pan African medical journalPubMeddocument de 2 observations

285 deathsAs of July 30, 2020, Kenya reported 285 deaths due to COVID-19.

KenyaCOVID-19observé July 30, 2020publié 2022Journal of global healthPubMeddocument de 24 observations

49,5 %Most participants (49.5%) had mild COVID-19.

KenyaCOVID-19publié 2022PloS onePubMeddocument de 7 observations

35,4 %Among hospitalized COVID-19 patients in Kenya with underlying conditions, 35.4% died.

KenyaCOVID-19publié 2025Global health actionPubMeddocument de 11 observations

The recombinant FY.4 SARS-CoV-2 variant was the dominant circulating variant in Kenya between April and July 2023.

KenyaCOVID-19observé April and July 2023publié 2025Virus evolutioneurope_pmcdocument de 4 observations

1,66 aPRAmong participants in Kenya, Uganda, Tanzania, and Nigeria between 19 July 2022 and 1 March 2024, adjusted prevalence ratio for SARS-CoV-2 infection was 1.66 among those who received at least one dose of a COVID-19 vaccine compared to those who received no doses.

Kenya · Nigeria · Ouganda · TanzanieCOVID-19observé 19 July 2022 to 1 March 2024publié 2025BMC infectious diseasesPubMeddocument de 8 observations

6 190 casesAs of 30th June 2020, over 6,190 COVID-19 cases had been reported in Kenya.

KenyaCOVID-19observé 30th June 2020publié 2020The Pan African medical journalPubMeddocument de 2 observations

41,4 %Vaccine hesitancy was estimated at 41.4% among the unvaccinated group in a sample of pregnant women in Kenya.

KenyaCOVID-19observé 2022publié 2024International journal of environmental research and public healtheurope_pmcdocument de 5 observationsDOI 10.3390/ijerph21010098

21,2 %Among 609 cases with underlying medical conditions in Kenya, 129 (21.2%) had multiple conditions.

KenyaCOVID-19publié 2022Journal of global healthPubMeddocument de 24 observations

8 casesAmong 97 SARS-CoV-2 cases in Laikipia county, Kenya, the Alpha variant was detected in 8 cases.

KenyaCOVID-19observé 24th April to 31st December 2021publié 2023Temporal distribution and clinical characteristics of the Alpha, Delta and Omicron SARS-Coeurope_pmcdocument de 10 observations

61,1 %Among patients with underlying conditions in Kenya's hospitalized COVID-19 cohort, hypertension was present in 61.1%.

KenyaCOVID-19 · hypertension artériellepublié 2025Global health actionPubMeddocument de 11 observations

75 introductionsWe estimated 75 independent SARS-CoV-2 introductions into Laikipia county, Kenya.

KenyaCOVID-19observé 24th April to 31st December 2021publié 2023Temporal distribution and clinical characteristics of the Alpha, Delta and Omicron SARS-Coeurope_pmcdocument de 10 observations

3,3 %Among 582 participants in Western Kenya who were retrospectively tested from January through March 2020, 19 (3.3%) had detectable SARS-CoV-2 antibodies.

KenyaCOVID-19observé January through March 2020publié 2021AIDS (London, England)PubMeddocument de 3 observations

43 %The most common symptoms at admission among hospitalized SARS-CoV-2-infected patients were cough (337, 43%), loss of taste or smell (279, 35%), and fever (126, 16%).

KenyaCOVID-19publié 2022BMJ openPubMeddocument de 7 observations

46,8 %Among 609 cases with underlying medical conditions in Kenya, 285 (46.8%) had hypertension.

KenyaCOVID-19publié 2022Journal of global healthPubMeddocument de 24 observations

24,7 %In Kilifi, seroprevalence of anti-SARS-CoV-2 IgG was 24.7% (95% CI 17.5–32.6%) at the end of the study period.

KenyaCOVID-19publié 2022PLOS global public healtheurope_pmcdocument de 7 observationsDOI 10.1371/journal.pgph.0000883

The first wave of the SARS-CoV-2 pandemic peaked before the end of July 2020 in the major urban counties of Kenya.

KenyaCOVID-19observé before the end of July 2020publié 2021Wellcome open researcheurope_pmcdocument de 2 observations